Published in:
01-12-2021 | COVID-19 | Letter to the Editor
Inflammatory biomarkers at hospital discharge are associated with readmission and death in patients hospitalized for COVID-19
Authors:
Marleen A. Slim, Brent Appelman, Marcella C. A. Müller, Matthijs C. Brouwer, Alexander P. J. Vlaar, W. Joost Wiersinga, Lonneke A. van Vught, the Amsterdam UMC COVID-19 biobank study group
Published in:
European Journal of Clinical Microbiology & Infectious Diseases
|
Issue 12/2021
Login to get access
Excerpt
Even though the survival of patients admitted with coronavirus disease 2019 (COVID-19) has increased with approximately 20% over the past year [
1], readmission and mortality rates remain high (19.9% and 9.1%, respectively, within 2 months after hospital discharge (ward and intensive care unit (ICU)—admissions combined) [
2]. In community-acquired pneumonia, elevated interleukin (IL)-6 and IL-10 at hospital discharge are associated with mortality in the subsequent 3 and 6 months, despite initial clinical recovery [
3]. We aim to evaluate whether elevated levels of IL-6 and IL-10 at hospital discharge are associated with readmissions and mortality in the following 12 months in patients with COVID-19. …
